<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765713</url>
  </required_header>
  <id_info>
    <org_study_id>HULP PI-719</org_study_id>
    <nct_id>NCT00765713</nct_id>
  </id_info>
  <brief_title>Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias</brief_title>
  <acronym>SAHS-ICD</acronym>
  <official_title>Sleep Apnea-hypopnea Syndrome and Ventricular Arrhythmias in Patients With Systolic Ventricular Dysfunction and Implantable Cardioverter-defibrillator. Incidence and Effect of CPAP Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Virgen de la Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen Macarena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      The CPAP treatment diminishes the effect of ventricular arrhythmias in patients with ischemic&#xD;
      heart disease or dilated myocardiopathy, systolic ventricular disfunction and sleep&#xD;
      apnea-hypopnea syndrome (SAHS)Objectives: To analyze the incidence of ventricular arrhythmias&#xD;
      (premature ventricular beat, non-sustained ventricular tachycardia and sustained ventricular&#xD;
      tachycardia) and appropriate defibrillator therapies in patients with ischemic heart disease&#xD;
      or dilated myocardiopathy, moderate-severe left ventricular dysfunction,with an implantable&#xD;
      cardioverter-defibrillator (ICD) and sleep apnea. To study the effect of CPAP on the cardiac&#xD;
      arrhythmias and on the number of appropriate defibrillator therapies.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Parallel, randomized and single-blinded multicentric study to compare CPAP vs.&#xD;
      hygienic-dietetic recommendations.&#xD;
&#xD;
      Patients with SAHS (AHI≥15) and systolic left ventricle dysfunction patients with an ICD.&#xD;
&#xD;
      Duration: 24 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives:&#xD;
&#xD;
      To compare the prevalence of SAHS in patients with ischemic heart disease or dilated&#xD;
      myocardiopathy and moderate-severe left ventricle dysfunction with ICD with that of the&#xD;
      general population. To study the incidence of supraventricular arrhythmias (atrial&#xD;
      fibrillation, atrial flutter or supraventricular tachycardia) and inappropriate defibrillator&#xD;
      therapies in these patients. To value the effect of the treatment with CPAP on the above&#xD;
      mentioned arrhythmias. To relate the effect of ventricular and supraventricular arrhythmias&#xD;
      with sleep parameters, cardiovascular biomarkers, inflammation and oxidative stress. To&#xD;
      evaluate the long-term effect of the CPAP on systemic biomarkers in patients with ischemic&#xD;
      heart disease or dilated myocardiopathy and moderate-severe left ventricle dysfunction. To&#xD;
      evaluate the long-term effect of CPAP on the quality of life in these patients.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      224 patients with ischemic heart disease or dilated myocardiopathy and moderate-severe left&#xD;
      ventricle dysfunction with ICD will be included to randomize 19 SAHS subjects for arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of appropriate defibrillator therapies</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AHI, incidence of premature ventricular beats and non-sustained ventricular tachycardia. Plasmatic levels of C-reactive protein, homocystein, pro-BNP, sTNFαR-I, IL-1b, IL-2, IL-6, IL-8, IL-8 and 8-isoprostane</measure>
    <time_frame>24 moths</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Ventricular Arrythmias</condition>
  <condition>Systolic Left Ventricle Dysfunction</condition>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous positive airway pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hygienic-dietetic recommendations</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nasal continuous positive airway pressure</intervention_name>
    <description>Nocturnal</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous diagnostic of ischaemic heart disease of dilated myocardiopathy&#xD;
&#xD;
          -  Ejection fraction of left ventricle &lt; 40%&#xD;
&#xD;
          -  Patients with implantable cardioverter-defibrillator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diurnal hypersomnolence with EES &gt; 16&#xD;
&#xD;
          -  Morbid obesity (BMI &gt; 35 Kg/m2).&#xD;
&#xD;
          -  Moderate-severe chronic obstructive pulmonary disease (FEV1/FVC &lt; 70 % and FEV1 &lt; 80 %&#xD;
             of reference).&#xD;
&#xD;
          -  Known thyroid disease.&#xD;
&#xD;
          -  Previous treatment with CPAP.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Garcia-Rio, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2013</last_update_posted>
  <responsible_party>
    <name_title>Rafael Peinado Peinado</name_title>
    <organization>Hospital Universitario La Paz</organization>
  </responsible_party>
  <keyword>Sleep apnea</keyword>
  <keyword>CPAP</keyword>
  <keyword>Ventricular arrhythmias</keyword>
  <keyword>Defibrillator therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

